Automation and High-Throughput Technologies
1536 and beyond: HT miniaturization while maintaining physiological relevance
Over recent years, AstraZeneca has worked to develop a high throughput mass spectrometry platform which utilizes the speed and contactless nature of acoustics as a sample introduction technology. Fully automated acoustic mist ionization mass spectrometry platforms are now routinely used to support biochemical HTS campaigns, to date over 10 million samples have been successfully screened against more than 10 different enzyme targets using this technology.
Having established a primary role for AMI-MS we are now looking to expand the application space where the technology could add value to early drug discovery. We have recently started to evaluate the impact of AMI-MS for metabolomic analysis of cell lysates, primarily within the early toxicology screening area.
In December 2018, AstraZeneca and collaborators at several Swedish academic institutions and SME’s were awarded a phase 2 grant from Sweden’s Innovation Agency, Vinnova. The aim of the collaboration is to develop technologies and workflows to enable primary patient derived disease cells to be utilized in the early phase of drug discovery.
This presentation will focus on the continued development of AMI-MS within AZ and how we are applying high throughput mass spectrometry to enable clinical samples to be assessed in the early phases of drug discovery.